Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib in advanced solid tumors with FGFR mutations
NCT04003623Phase 2Terminated
- Sponsor
- Incyte
- Start
- Oct 2019
- Primary completion
- Jun 2020
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemigatinib in solid tumor, sponsored by Incyte. Primary endpoint: Objective Response Rate up to 6 months. Started Oct 2019; status: terminated.
02
Drugs
pemigatinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04003623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04003623.